The microbiota-gut-brain axis: novel mechanisms and therapeutic frontiers in obesity and type 2 diabetes Authors: Kaile Ma, Qiqi Zhang, Rui Hao, Xiao Sun, Jing Jia, Min Li Published: 2026 ABSTRACT The microbiota-gut-brain axis (MGBA) is a bidirectional network linking gut microbes to the CNS. This review elucidates how microbial messengers—short-chain fatty acids, bile acids, neuroactive metabolites, and extracellular vesicles—drive obesity and type 2 diabetes via neural, endocrine, and immune pathways. MGBA dysregulation triggers hypothalamic dysfunction, adipose inflammation, incretin axis impairment, and β‑cell failure. We discuss MGBA—targeted therapies and their translational challenges. Introduction There exists an active bidirectional communication between the gut microbiota and the central nervous system (CNS), known as the “microbiota-gut-brain axis” (MGBA). This axis integrates intestinal signals and brain function through neural, endocrine, immune, and metabolic pathways and has emerged as a central network that orchestrates host physiology and drives pathological states1,2. Although existing research has largely focused on the contribution of the MGBA in neurodevelopment and psychiatric disorders, its importance in systemic metabolic control is increasingly being established3. Beyond participating in fundamental functions such as nutrient harvesting from the diet, maintenance of the intestinal barrier, and immune modulation, the gut microbiota also produces or remodels metabolic messengers—such as short-chain fatty acids (SCFAs), bile acids (BAs), and neuroactive substances—that can directly and remotely alter the CNS’s energy sensing and glucolipid metabolic programs, thereby establishing host metabolic homeostasis4–9. Metabolic diseases, particularly obesity and type 2 diabetes (T2DM), pose a severe global health challenge. According to the 2021 Global Burden of Disease Study, metabolic risk factors account for approximately 27% of annual global mortality, equating to roughly 18 million deaths10. Current therapeutic options for obesity and T2DM include lifestyle interventions, bariatric surgery, and pharmacotherapies. For T2DM, metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and insulin remain cornerstones of glucose management. For obesity, glucagon-like peptide-1 (GLP-1)-based therapies have emerged as effective agents for both glycemic control and weight reduction. However, despite these available options, limitations persist—including inadequate response in some patients, weight regain after discontinuation of GLP-1 agonists, gastrointestinal side effects, and challenges in long-term adherence11. These unmet clinical needs underscore the pressing necessity to explore novel mechanisms and therapeutic targets for metabolic disorders. Recent studies have established a close link between the MGBA and metabolic diseases. Patients with obesity and T2DM often exhibit specific gut microbiota dysbiosis, characterized by a reduced abundance of butyrate-producing bacteria, including Faecalibacterium prausnitzii and Roseburia intestinalis, and this disturbance can precede the onset of disease by several years, suggesting a causal role12,13. Notably, disruptions in the gut microbiota early in life program long-term metabolic risk by altering the development of the immune system and metabolic tissues8. Dysregulation of the MGBA drives metabolic disorders through multi-layered mechanisms: it can disrupt the hypothalamic appetite regulatory center, impair the secretion and signaling of gut-derived hormones (e.g., GLP-1, PYY), induce chronic inflammation in adipose tissue, and ultimately lead to insulin resistance and β-cell dysfunction8,14. Interestingly, interventions targeting the MGBA have already demonstrated potential, with SCFA supplementation showing promise for improving metabolic homeostasis in preliminary clinical studies and animal models15,16. However, despite the relatively advanced understanding of the MGBA in neuropsychiatric contexts, its systemic mechanisms of action in metabolic diseases such as obesity and T2DM remain incompletely delineated3,17. Existing reviews often focus on individual metabolites or pathways and fail to comprehensively elucidate how diverse microbial messengers cooperate through the integrated MGBA network to synergistically drive the dynamic, vicious cycle from intestinal ecological dysbiosis to central and peripheral metabolic dysregulation. Furthermore, translating this mechanistic knowledge into precise interventional strategies that extend beyond current GLP-1-based therapies remains a critical challenge in the field. Therefore, this review aims to systematically summarize and integrate the latest evidence, focusing on key “microbial messengers” such as SCFAs, BAs, neuroactive metabolites, and microbial extracellular vesicles (EVs; nanometer-scale particles released by bacteria that carry bioactive cargo including proteins, lipids, and nucleic acid), to elaborate in detail their core mechanistic roles in the development and progression of obesity and T2DM through the MGBA. We will particularly highlight the interactive crosstalk among different messengers and pathways and the resultant vicious cycles. Finally, we will prospectively discuss the clinical translational potential and challenges of innovative therapeutic strategies targeting the MGBA (such as precision prebiotics/probiotics, receptor modulators, and neuromodulation technologies), aiming to provide new theoretical frameworks and intervention insights for the prevention and treatment of metabolic diseases. Microbial messengers and signaling pathways of the MGBA The gut microbiota generates a diverse array of small molecules and nanoparticles through its complex metabolic activities. These products are not merely metabolic byproducts but function as key “chemical messengers” mediating MGBA functions. Capable of crossing the intestinal barrier and entering circulation, they remotely regulate host metabolic and immune homeostasis by interacting with specific receptors or recognition mechanisms on host cells, thereby forming the material basis for the bidirectional communication within the MGBA18. These messengers operate not in isolation but through three highly coordinated and interconnected core pathways—neural, endocrine, and immune—that together establish a dynamic network controlling host appetite, energy balance, and glucose/lipid metabolism19. Dysregulation of this network is a central mechanism in the development and progression of obesity and T2DM. The following sections first describe the four major classes of microbial messengers and then explain how they operate through these integrated signaling pathways. SCFAs: central regulators of energy homeostasis via the gut-brain axis SCFAs are specialized microbial metabolites and represent the major end products of dietary fiber fermentation, with acetate, propionate, and butyrate accounting for over 95% of the total SCFA pool20. They fuel colonic epithelial cells and also act as pleiotropic signaling molecules. Their biological actions are primarily executed through two key mechanisms. First, SCFAs bind to and activate specific G protein-coupled receptors (GPCRs), such as free fatty acid receptor 2 (FFAR2, also known as GPR43), free fatty acid receptor 3 (FFAR3 or GPR41), and the butyrate-specific receptor hydroxycarboxylic acid receptor 2 (HCAR2, also designated as GPR109A)21,22. These receptors are widely distributed in enteroendocrine cells (EECs), immune cells, and nerve terminals, enabling SCFAs to rapidly stimulate gut hormone secretion, modulate immune responses, and influence autonomic nerve activity23. Second, acting as histone deacetylase inhibitors (HDAC)—particularly butyrate and propionate—SCFAs induce long-term “reprogramming” of gene expression in host cells (such as intestinal epithelial cells, immune cells, and neurons) through epigenetic modifications, thereby influencing barrier integrity, inflammatory status, and neuroplasticity24,25. Through these mechanisms, SCFAs serve as critical chemical bridges that facilitate communication along multiple functional pathways. In the neural pathway, SCFAs activate FFAR3 on vagal afferent fibers and intrinsic enteric neurons, directly increasing sympathetic tone and altering local neural activity to influence systemic metabolism26,27. In the endocrine pathway, SCFAs act as endogenous agonists for FFAR2/FFAR3 on enteroendocrine L cells, potently stimulating GLP-1 and PYY secretion, which in turn suppresses appetite and enhances insulin secretion28. SCFAs also influence the hypothalamic-pituitary-adrenal (HPA) axis by activating GPR41 and GPR43 in the hypothalamic paraventricular nucleus (PVN) and adrenal gland, thereby modulating cortisol release and glucose metabolism29,30. In the immune pathway, butyrate inhibits HDACs in intestinal epithelial cells, increasing regulatory T cell differentiation and upregulating tight junction protein expression, thereby maintaining intestinal barrier integrity and suppressing systemic inflammation (Fig. 1)25.Fig. 1Schematic diagram of key microbial messengers, their central network, and signaling pathways in MGBA.This figure summarizes the four major classes of signaling molecules directly produced by gut microbiota or modified by them. ① SCFAs. Dietary fibers are fermented into SCFAs (acetate, propionate, butyrate). They exert pleiotropic effects as endogenous ligands, activating specific GPCRs (FFAR2, FFAR3, HCAR2) on EECs, immune cells, and nerve endings, and acting as HDAC inhibitors to maintain barrier integrity. ② Microbiota-modified BAs. Primary BAs synthesized by the liver are converted by gut microbiota enzymes (e.g., 7α-dehydroxylase) into secondary BAs. BAs signal through FXR in ileal epithelial cells and membrane receptor TGR5 on intestinal L cells (stimulating GLP-1) and brown adipose tissue (BAT; promoting thermogenesis). Notably, specific secondary BAs enter the peripheral circulation, cross the blood-brain barrier (BBB), and act on TGR5 located in the neurons of hypothalamic nuclei to regulate appetite. ③ Neuroactive microbial metabolites. Gut bacteria synthesize neuroactive compounds (e.g., glutamate conversion to GABA via glutamate decarboxylase [GAD]) and modulate the 5-HT system by affecting EC cells. These locally affect the ENS and vagal afferents. ④ Microbial EVs. Bacteria release nanoscale EVs carrying bioactive substances. EVs cross the intestinal barrier into the systemic circulation, cross the BBB, and are taken up by resident immune cells like microglia, thereby regulating neuroinflammation and metabolic homeostasis. Created in BioRender. Ma, K. (2026). BioRender.com/9uxbihd. Schematic diagram of key microbial messengers, their central network, and signaling pathways in MGBA. This figure summarizes the four major classes of signaling molecules directly produced by gut microbiota or modified by them. ① SCFAs. Dietary fibers are fermented into SCFAs (acetate, propionate, butyrate). They exert pleiotropic effects as endogenous ligands, activating specific GPCRs (FFAR2, FFAR3, HCAR2) on EECs, immune cells, and nerve endings, and acting as HDAC inhibitors to maintain barrier integrity. ② Microbiota-modified BAs. Primary BAs synthesized by the liver are converted by gut microbiota enzymes (e.g., 7α-dehydroxylase) into secondary BAs. BAs signal through FXR in ileal epithelial cells and membrane receptor TGR5 on intestinal L cells (stimulating GLP-1) and brown adipose tissue (BAT; promoting thermogenesis). Notably, specific secondary BAs enter the peripheral circulation, cross the blood-brain barrier (BBB), and act on TGR5 located in the neurons of hypothalamic nuclei to regulate appetite. ③ Neuroactive microbial metabolites. Gut bacteria synthesize neuroactive compounds (e.g., glutamate conversion to GABA via glutamate decarboxylase [GAD]) and modulate the 5-HT system by affecting EC cells. These locally affect the ENS and vagal afferents. ④ Microbial EVs. Bacteria release nanoscale EVs carrying bioactive substances. EVs cross the intestinal barrier into the systemic circulation, cross the BBB, and are taken up by resident immune cells like microglia, thereby regulating neuroinflammation and metabolic homeostasis. Created in BioRender. Ma, K. (2026). BioRender.com/9uxbihd. BAs: microbial-remodeled metabolic messengers Although primarily synthesized by the host, the diversity, activity, and gut-brain communication functions of BAs are entirely dependent on microbial modification, making them an exemplary model of host-microbiota co-metabolic signaling within the MGBA31–33. BAs are synthesized in the liver, with their classical function being the facilitation of lipid digestion. However, the gut microbiota remodels the composition and signaling properties of the BA pool by converting primary BAs into secondary BAs through microbial-specific enzymes (e.g., bile salt hydrolase, 7α-dehydroxylase)34. Microbiota-remodeled BAs signal through two principal receptors: the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5)35. Among the secondary BAs produced by microbial 7α-dehydroxylation, deoxycholic acid (DCA) is a key example that has been implicated in metabolic regulation. FXR is a nuclear receptor; most BAs are reabsorbed in the ileum, where they activate local FXR, inducing the synthesis and secretion of fibroblast growth factor 15/19 (FGF15/19). This, in turn, suppresses BA biosynthesis, improves glucose metabolism, and enhances lipid homeostasis through the enterohepatic axis36. TGR5, on the other hand, is a membrane receptor. Its activation in intestinal L cells stimulates GLP-1 release via cAMP-PKA signaling; in brown adipose tissue, TGR5 activation enhances thermogenesis by upregulating uncoupling protein 1 (UCP1), thereby increasing energy expenditure24,37. Notably, certain BAs can cross the blood-brain barrier and directly act on TGR5 in brain regions such as the hypothalamus, participating in the regulation of appetite centers38,39. In addition, central TGR5 signaling has been shown to regulate glucose homeostasis and insulin sensitivity40. BAs thus simultaneously engage multiple signaling pathways. In the neural pathway, secondary BAs activate TGR5 on intestinal vagal nerve fibers to transmit satiety signals to the brainstem and hypothalamus38,41. In the endocrine pathway, TGR5 activation on intestinal L cells stimulates GLP-1 release, which acts both locally on vagal afferents and systemically on pancreatic β-cells to enhance insulin secretion37. Through the enterohepatic axis, BA signaling via FXR regulates systemic glucose and lipid metabolism, serving as a paradigm for multidimensional communication within the MGBA (Fig. 1). Neuroactive metabolites: direct molecular dialogue between the gut microbiota and the nervous system The gut microbiota synthesizes a variety of neuroactive molecules identical to those in the host nervous system, providing a most direct chemical language for gut-brain axis communication42. Among these, γ-aminobutyric acid (GABA) and serotonin (5-HT) have been the most extensively studied. GABA is the major inhibitory neurotransmitter in the CNS and is produced by gut bacteria such as Escherichia spp., Lactobacillus spp., and Bacteroides spp. via the enzyme glutamate decarboxylase43. Intestinal GABA activates GABA receptors on enteric neurons of the enteric nervous system (ENS) and vagal afferent fibers, reducing gastrointestinal motility and modulating visceral sensation; it also influences CNS activity, suppressing appetite and regulating emotional behaviors44,45. The gut is the body’s principal source of 5-HT, storing over 90% of total body 5-HT. The gut microbiota controls 5-HT production by regulating enterochromaffin (EC) cell function and tryptophan metabolism46. Gut-derived 5-HT promotes gastrointestinal motility and also activates vagal afferent fibers or enters the circulation to modulate hypothalamic circuits that control appetite, mood, and energy balance47. These microbially derived neurotransmitters establish a rapid and specific “gut-neural” communication channel. GABA activates GABA receptors on enteric neurons and vagal afferent fibers, reducing neuronal excitability and slowing gastrointestinal transit while transmitting satiety signals to the brain44. 5-HT activates 5-HT receptors on vagal afferent terminals, triggering action potentials that propagate to the nucleus tractus solitarius (NTS) and ultimately to the hypothalamus, where they modulate appetite and energy balance41,48. This pathway represents a rapid reflex that tightly links the state of the gut microbiota with CNS function (Fig. 1). Microbial EVs: a delivery system for bioactive cargo In addition to soluble small-molecule metabolites, gut bacteria also interact with the host by releasing nanometer-sized EVs49. These nanosized vesicles carry diverse bioactive components, including proteins, lipids, and various nucleic acids, representing a unique mode of inter-kingdom information transfer. Within the local gut environment, they bind to epithelial cells and deliver signaling molecules that upregulate the expression of tight junction proteins (e.g., occluding, ZO-1), thereby maintaining intestinal barrier integrity50. Moreover, these vesicles resist degradation, enabling them to cross the intestinal barrier, enter systemic circulation, and reach distant organs, including the brain51. Studies have shown that microbial EVs reaching the CNS are internalized by microglia, where their bioactive cargo suppresses neuroinflammatory responses, modulates microglial function, and influences systemic metabolic states, thereby achieving precise, long-distance gene and signal modulation from the gut to the brain52,53. This represents a novel, nanoparticle-mediated direct “gut-brain” axis for material transport and information exchange. In the immune pathway, microbial EVs carrying LPS, flagellin, and bacterial DNA activate TLR4, TLR5, and TLR9 on intestinal epithelial cells and immune cells, triggering NF-κB signaling and modulating local and systemic inflammatory responses54,55. By crossing the intestinal barrier and reaching the brain, EVs serve as a key link between gut dysbiosis and neuroinflammation, contributing to the pathogenesis of metabolic diseases (Fig. 1). Integration of signaling pathways: a dynamic regulatory network The neural, endocrine, and immune pathways described above do not operate in isolation. Instead, they are highly integrated, forming a dynamic network that enables the gut microbiota to exert systemic control over host metabolism. By controlling immune homeostasis, microbial messengers establish a critical pathway linking the gut environment to systemic inflammatory states (including those in the brain), profoundly influencing metabolic health56,57. The ENS plays a central role in this integration, receiving signals from EECs, immune cells, and microbial messengers, and regulating intestinal immune responses, nutrient sensing, and microvascular circulation through local reflexes58. The ENS transmits integrated information to the CNS via the vagus nerve or spinal afferent nerves, while also receiving descending regulatory inputs from the CNS, forming a sophisticated feedback loop59. The vagus nerve itself serves as a critical hub for signal integration. It not only conveys sensory information from the gut to the brainstem but also mediates the cholinergic anti-inflammatory pathway, whereby efferent vagal fibers modulate immune responses and reduce systemic inflammation60. This pathway has been shown to regulate local pancreatic inflammation and improve insulin sensitivity via M2 macrophage polarization. In obesity, this rapid feedback pathway is often functionally impaired. For instance, diet-induced obesity has been shown to reduce the sensitivity of vagal afferent neurons to satiety signals such as cholecystokinin (CCK) and leptin, thereby blunting postprandial satiety signaling and contributing to increased food intake61. HPA axis provides another important humoral pathway connecting the gut microbiota, neuroendocrine function, and systemic metabolic status. Microbial messengers such as SCFAs can act directly on GPR41 and GPR43 in the PVN and adrenal gland, or indirectly via the vagus nerve, to regulate corticotropin-releasing hormone (CRH) release and subsequent cortisol secretion, thereby influencing glucose metabolism, immune homeostasis, and appetite62,63. Dysregulation of this integrated network is a central mechanism in obesity and T2DM, as will be discussed in detail in the following chapters. Metabolic microbial messengers: driving a vicious cycle of the gut-brain axis in obesity The development and progression of obesity are not merely a result of simple energy imbalance but are also critically driven by functional dysregulation of the MGBA system, which integrates and interacts with genetic, endocrine, metabolic, and environmental factors. Gut microbiota dysbiosis is not merely an accompanying phenomenon; instead, through the secretion of messengers–including SCFAs, BAs, neuroactive metabolites, and others–it induces coordinated disruption across the three core pathways (neural, endocrine, and immune). This actively programs a full-spectrum pathological state ranging from central regulatory failure and peripheral inflammatory dysregulation to the interruption of key chemical dialogues. This chapter will systematically elucidate how dysregulated microbial messengers construct a self-reinforcing vicious cycle that drives the pathological progression of obesity. Hypothalamic dysfunction: central integration of microbial signals in obesity The arcuate nucleus of the hypothalamus serves as a central hub for integrating peripheral energy signals and controlling energy balance. This nucleus contains two distinct populations of first-order neurons: the anorexigenic pro-opiomelanocortin (POMC) neurons, which promote satiety and increase energy expenditure, and the orexigenic agouti-related protein (AgRP) neurons, which stimulate appetite and reduce energy expenditure64. The functional integrity of this hub is profoundly influenced by the profile of microbial messengers originating from the gut, alongside classical metabolic and hormonal signals. The initiation and maintenance of obesity are intimately linked to the functional dysregulation of hypothalamic circuits induced by these microbial messengers, characterized by impaired insulin and leptin signaling, neuroinflammation, and altered neuronal activity65,66. The depletion of beneficial microbial messengers withdraws fundamental support for maintaining the delicate balance between anorexigenic (e.g., POMC) and orexigenic (e.g., AgRP) neuronal activity in the hypothalamus67,68. The exhaustion of SCFA-producing bacterial populations in the gut leads to decreased circulating levels of acetate, butyrate, and others. These SCFAs are essential metabolic regulators and signaling molecules required for the normal function of key neuronal circuits within the hypothalamic arcuate nucleus, such as POMC and AgRP neurons69. For example, colon-derived SCFAs like acetate support the glutamate-glutamine cycle in the hypothalamus, enhance GABAergic inhibitory signaling, thereby activating anorexigenic POMC neurons while inhibiting orexigenic AgRP neurons, promoting satiety69. This mechanism has been shown to be significantly attenuated in obesity70. Conversely, beneficial microbial interventions can downregulate NPY expression and upregulate POMC expression, thereby improving lipid metabolism, reducing weight gain, and restoring energy balance71. Evidence from both directions confirms the crucial role of microbial messengers in regulating the hypothalamic appetite center. The expansion of harmful microbial messengers triggers and sustains neuroinflammation and insulin resistance in the hypothalamus. High-fat diet-induced gut microbiota dysbiosis elevates circulating LPS levels and reduces SCFAs concentrations72. This imbalance delivers inflammatory signals to the hypothalamus via the circulation, activating microglia and promoting the release of IL-1β and TNF-α. These cytokines disrupt insulin signaling by inducing serine phosphorylation of insulin receptor substrates (IRS) proteins, thereby impairing hypothalamic insulin sensitivity72. In contrast, beneficial messengers like butyrate and propionate can cross the blood-brain barrier. By inhibiting histone deacetylases and activating receptors such as GPR43, they directly modulate the hypothalamic inflammatory microenvironment and restore insulin sensitivity73. Deficiency of these beneficial metabolites thus contributes to the persistence of hypothalamic inflammation and insulin resistance, a key feature of obesity. Furthermore, gut microbiota dysbiosis increases HPA axis reactivity, raising cortisol levels, which promotes visceral fat accumulation and stimulates appetite. This, in turn, drives visceral fat accumulation and stimulates appetite, establishing a positive feedback loop whereby stress promotes overeating, which in turn exacerbates obesity and further dysregulates the HPA axis74. Specific dietary patterns, such as a high-cholesterol diet, also prompt the gut microbiota to overproduce DCA. DCA interferes with gut hormone secretion by overactivating the TGR5 receptor on the surface of EECs, thereby undermining the protective effects of gut hormones like GLP-1 and PYY on the hypothalamus75. Therefore, hypothalamic dysfunction represents a critical consequence of altered microbial messenger signaling, which disrupts the normal neuroendocrine and immune regulation of energy homeostasis. This dysfunctional state is characterized by impaired responsiveness to peripheral metabolic signals, reduced sensitivity to gut-derived feedback signals, and altered autonomic and neuroendocrine outputs to peripheral tissues, thereby perpetuating the metabolic imbalances that underlie obesity. Adipose tissue as a central hub for inflammatory signal amplification and feedback Within the dynamic network of the MGBA, adipose tissue is far from a passive energy reservoir; rather, it serves as an active signaling hub that secretes adipokines and cytokines while receiving microbial-derived signals from the gut76. In turn, this reprogrammed adipose tissue broadcasts pathological signals to the brain, the intestine, and peripheral organs, thereby amplifying localized disturbances into systemic metabolic inflammation77. Dysregulated microbial messengers directly program the functional state of adipose tissue. Impairment of the intestinal barrier permits continuous influx of pathogen-associated molecular patterns (PAMPs), such as LPS, into the circulation. LPS activates TLR4 on adipose tissue macrophages, driving their polarization from an anti-inflammatory M2 to a pro-inflammatory M1 phenotype, with robust secretion of TNF-α and IL-6, thereby inducing local insulin resistance78. Concurrently, the depletion of protective microbial messengers dismantles the endogenous anti-inflammatory barrier. The reduction in SCFA-producing bacteria not only diminishes the direct anti-inflammatory and thermogenic effects of butyrate within adipose tissue--mediated via GPCR activation and HDAC inhibition79,80--but also leads to a decrease in specific microbially shaped secondary BAs, such as lithocholic acid. This, in turn, attenuates TGR5 receptor-mediated thermogenesis in white adipose tissue and systemic anti-inflammatory responses81. Certain gut commensal bacteria or their components can directly control adipose tissue immunity. For instance, the gut commensal Phascolarctobacterium faecium promotes macrophage polarization toward the anti-inflammatory M2 phenotype through its structural components binding directly to TLR2 on macrophages82. Consequently, the metabolic and immune phenotype of adipose tissue is directly “set” by the output signals from the gut microbiota. More critically, this metabolically dysregulated adipose tissue, in turn, becomes a potent source of feedback signals that erode the overall homeostasis of the MGBA. Adipose tissue containing activated pro-inflammatory macrophages continuously releases large amounts of inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α) and excessive free fatty acids into the circulation. These signals engage two interconnected positive feedback loops that perpetuate metabolic dysfunction: ascending to the brain, they can increase blood-brain barrier permeability, activate hypothalamic microglia, exacerbate neuroinflammation, and directly impair the function of neurons governing appetite and energy expenditure, thereby consolidating and worsening the failure of central command83–85; descending to the gut, these inflammatory factors and metabolites directly damage intestinal epithelial tight junctions and further increase gut permeability, aggravating endotoxemia and altering microbiota composition, thereby exacerbating the imbalance of microbial messengers at its source83. In this vicious cycle, adipose tissue plays the pivotal role of a central hub that receives, amplifies, and rebroadcasts the dysregulated signals of the MGBA. Impairment of the incretin axis by microbial messengers: disruption of gut-brain signaling in obesity The efficient operation of the MGBA depends on continuous chemical dialogue between the gut and the brain. GLP-1 and PYY, secreted by intestinal L cells, are core hormones mediating postprandial satiety and energy homeostasis, whose synthesis and release are precisely controlled by microbial messengers86. In obesity, the failure of this regulatory network disrupts gut-brain chemical dialogue, constituting a key pathological mechanism that disrupts energy balance87. First, gut microbiota dysbiosis depletes the key endogenous microbial agonists that drive hormone secretion. Obesity-associated dysbiosis, particularly the reduction in beneficial bacteria such as butyrate-producers, directly lowers butyrate, propionate, and other SCFAs in the colon and circulation. As critical endogenous agonists for FFAR2/3 on L cells, reduced SCFAs deprive L cells of a fundamental secretory stimulus88. Meanwhile, impaired microbial remodeling of the BA pool further disrupts hormonal secretion. A reduction in bile salt hydrolase-expressing beneficial bacteria impairs secondary BA generation, causing a relative or absolute deficiency of TGR5 agonists such as DCA89,90. Consequently, dual defects in both the quantity and quality of these messengers suppress incretin secretion at its source. Secondly, the systemic pathological environment shaped by the dysregulation of microbial messengers further impairs intestinal L cell function. This destructive process unfolds through multiple synergistic mechanisms: The circulating lipotoxic environment, exacerbated by microbial dysbiosis, elevates free fatty acids such as palmitate, which induce endoplasmic reticulum stress in L cells and reduce the protein levels of prohormone convertase 1/3 (PC1/3), impairing active GLP-1 production91. Concurrently, gut microbiota-derived SCFAs increase O-GlcNAcylation in intestinal epithelial cells, a modification that negatively regulates L cell development and function, directly suppressing GLP-1 synthesis92. Furthermore, chronic low-grade inflammation provides a persistently damaging milieu, as TNF-α and IL-6 directly inhibit L cell function93. Lipotoxicity, aberrant protein modification, and chronic inflammation together form a pathological network, initiated by microbial messenger dysregulation, leading to a comprehensive decline in the responsiveness of L cells to normal stimuli. Finally, the disruption of the incretin axis by microbial messengers interrupts both the rapid (neural) and slow (humoral) communication pathways of the MGBA. The direct consequence is a comprehensive weakening of gut-to-brain satiety signals. The rapid neural pathway is impaired because reduced local GLP-1 fails to activate vagal afferent fibers, blunting the immediate postprandial satiety reflex94. The sustained humoral pathway is compromised because low circulating GLP-1/PYY levels fail to maintain activation of central satiety neural networks, such as those in the hypothalamus, making it difficult to sustain a prolonged state of fullness95. This communication breakdown intertwines with the aforementioned central insulin resistance and the inflammatory signal feedback from adipose tissue, collectively closing the final pathological loop driving obesity: the negative feedback regulation of energy intake is completely dismantled, allowing a sustained positive energy balance. In turn, the progressively worsening metabolic environment further exacerbates gut microbiota dysbiosis and messenger imbalance, trapping the entire system in a vicious cycle that is difficult to reverse. In summary, the development and progression of obesity can be understood as a manifestation of systemic dysregulation within the MGBA. This process originates from disturbances in gut microbial ecology and the resultant imbalance of microbial-derived metabolic messengers. These changes subsequently interact through neural, endocrine, and immune pathways, leading concurrently to impaired regulatory function of the hypothalamic energy center, transformation of adipose tissue into an inflammatory metabolic organ, and attenuation of incretin axis signaling. These pathological alterations form a self-reinforcing feedback loop via persistent inflammatory signaling, abnormal neuroendocrine output, and exchange of metabolites. This cycle ultimately drives the organism toward a maladaptive state characterized by continuously increased energy storage and restricted energy expenditure, representing a new pathophysiological setpoint that perpetuates obesity, see Fig. 2.Fig. 2The mechanism of MGBA in obesity.The functional states of the microbiota-intestine-brain axis in healthy (left) and obese (right) conditions were systematically compared. The main pathological changes include: ① Disordered intestinal flora leads to a decrease in beneficial metabolites (SCFAs, secondary BAs) and an increase in LPS translocation; ② Dysfunction of L cells results in a reduction in GLP-1/PYY secretion; ③ Systemic low-grade inflammatory state; ④ Destruction of the balance of appetite neurons by hypothalamic neuroinflammation; ⑤ Weakened sympathetic nerve output and inflammation in adipose tissue; ⑥ Feedback of fat-derived inflammatory signals intensifies intestinal and systemic inflammation, forming a vicious cycle. Blue/green indicates protective pathways, red/orange indicates pathogenic pathways; solid arrows represent normal/enhanced signals, and dashed arrows represent weakened signals. Created in BioRender. Ma, K. (2026). B. The mechanism of MGBA in obesity. The functional states of the microbiota-intestine-brain axis in healthy (left) and obese (right) conditions were systematically compared. The main pathological changes include: ① Disordered intestinal flora leads to a decrease in beneficial metabolites (SCFAs, secondary BAs) and an increase in LPS translocation; ② Dysfunction of L cells results in a reduction in GLP-1/PYY secretion; ③ Systemic low-grade inflammatory state; ④ Destruction of the balance of appetite neurons by hypothalamic neuroinflammation; ⑤ Weakened sympathetic nerve output and inflammation in adipose tissue; ⑥ Feedback of fat-derived inflammatory signals intensifies intestinal and systemic inflammation, forming a vicious cycle. Blue/green indicates protective pathways, red/orange indicates pathogenic pathways; solid arrows represent normal/enhanced signals, and dashed arrows represent weakened signals. Created in BioRender. Ma, K. (2026). B. Metabolic microbial messengers: mechanisms of action within the gut-brain axis in T2DM T2DM represents a critical stage in the progression of metabolic disease, arising from the convergence of sustained dysregulation within the MGBA and other metabolic, genetic, and environmental factors96,97. As the disturbance of the MGBA evolves from an early state of positive energy balance to a systemic decompensated condition characterized by hyperglycemia and insulin resistance, the detrimental effects of microbial messengers deepen and expand97. The core pathology lies in the fact that dysregulated microbial messengers no longer merely modulate appetite and energy storage but systematically erode the integrity of insulin signaling and directly assault the core units of insulin secretion. Through the intertwined actions of neural, endocrine, and immune pathways, they collectively drive the comprehensive collapse of glucose homeostasis57. Systemic insulin resistance: from central to peripheral disruption In the pathogenesis of T2DM, gut microbial messengers disrupt insulin signaling throughout the body. Its effects span from the “command center” within the CNS to the “executive units” in peripheral metabolic organs, collectively leading to a comprehensive imbalance in glucose homeostasis. First, dysregulated microbial messengers contribute to central insulin resistance by triggering hypothalamic inflammation. Long-term high-fat diet-induced gut dysbiosis elevates circulating LPS and reduces SCFA levels98. This imbalanced environment activates hypothalamic microglia, which release inflammatory cytokines that impair insulin receptor signaling (PI3K-Akt-FoxO1) in neurons, thereby disrupting the hypothalamus’s ability to suppress hepatic glucose production via the autonomic nervous system99–101. The core consequence is the loss of central inhibition of hepatic gluconeogenesis, leading to inappropriate activation that contributes to fasting hyperglycemia102. Meanwhile, gut-derived pathogenic messengers target the liver and skeletal muscle via the portal vein and systemic circulation. When gut microbiota dysbiosis is accompanied by impaired intestinal barrier function, bacterial LPS translocates into the portal vein and activates Kupffer cells, the resident macrophages of the liver. This activation triggers the release of large quantities of pro-inflammatory cytokines such as TNF-α and IL-1β through the TLR4/NF-κB pathway103. These inflammatory mediators activate JNK and IKKβ, which phosphorylate IRS-1 on serine residues, blocking insulin signal transduction in hepatocytes104. This process may be further exacerbated by an abnormal elevation of hepatotoxic DCA within the microbially remodeled BA pool105. In skeletal muscle, systemic low-grade inflammation driven by gut leakage and adipose tissue inflammation impairs insulin signaling via similar JNK/IKKβ-mediated IRS serine phosphorylation106. Conversely, SCFAs can partially counteract this damage by activating AMPK and suppressing inflammatory pathways107,108. Ultimately, central and peripheral insulin resistance reinforce each other through a positive feedback loop initiated by microbial messenger dysregulation. A dysfunctional hypothalamus further impairs insulin sensitivity in the liver and adipose tissue via imbalanced autonomic output–characterized by sympathetic overexcitation and parasympathetic suppression109,110. Conversely, dysfunctional peripheral organs release large amounts of free fatty acids and pro-inflammatory factors into the circulation, which in turn act on the hypothalamus, inducing mitochondrial dysfunction and endoplasmic reticulum stress that exacerbate central insulin resistance and neuroinflammation111,112. The establishment of this integrated gut-brain-peripheral organ communication network marks the stabilization of insulin resistance from a functional impairment into a self-sustaining pathological state. Secretory dysfunction: from the gut-brain-pancreas axis to loss of β-cell identity In the progression of T2DM, the persistent presence of insulin resistance poses a formidable challenge to pancreatic β-cells. Dysregulation of the MGBA permeates this entire process, spanning from upstream neuroendocrine control disturbances to downstream β-cell dedifferentiation and eventual failure. Upstream, disruption of microbial messengers disrupts the finely tuned neuroendocrine regulatory network of the gut-brain-pancreas axis. On one hand, a high-fat diet increases acetate production, which activates the parasympathetic nervous system, thereby stimulating ghrelin secretion and enhancing glucose-stimulated insulin secretion. This premature and excessive secretory demand accelerates β-cell exhaustion75,113. On the other hand, persistent hyperglycemia and hyperlipidemia downregulate GLP-1 receptor expression on pancreatic β-cells and hypothalamic neurons and may even induce GLP-1 resistance in enteric neurons, thereby weakening this crucial gut-brain insulinotropic pathway114,115. At the β-cell level, dysfunction and dedifferentiation are similarly driven by the systemic environment shaped by microbial messengers. Multiple stressors that drive β-cell dedifferentiation—including endoplasmic reticulum stress, glucolipotoxicity, mitochondrial dysfunction, and amyloid deposition—are fundamentally linked to gut microbiota dysbiosis116. For instance, systemic inflammation exacerbated by microbial dysbiosis and the accumulation of branched-chain amino acids persistently activate mTORC1 and NF-κB, which suppresses autophagy and induce endoplasmic reticulum stress, synergistically impairing insulin synthesis/secretion and promoting β-cell apoptosis117,118. At the transcriptional level, chronic stressors such as hyperglycemia downregulate core β-cell transcription factors (e.g., PDX1, NKX6.1, MAFA) and upregulate dedifferentiation markers such as ALDH1A3, causing β-cells to lose their mature secretory phenotype and potentially transdifferentiate into other cell types119–121. This process may be remotely regulated by signals carried within EVs derived from the gut microbiota122. Therefore, the failure of β-cells is not an isolated event but rather represents the focal manifestation of systemic MGBA dysregulation specifically within the pancreas as the terminal target organ. Driven by microbial messengers, insulin resistance increases the functional burden on β-cells, while concurrent environmental factors such as inflammation and glucolipotoxicity impair their function and viability. This ultimately results in secretory decompensation and a reduction in β-cell mass, culminating in the fatal transition from compensatory hyperinsulinemia to absolute insulin deficiency. Gut-derived metabolic inflammation: systemic dissemination and the vicious cycle of gut-brain axis immune dysregulation in T2DM The progression of T2DM is closely associated with metabolism-related inflammation of intestinal origin, driven by dysregulated immune communication within the MGBA. Imbalanced microbial messengers compromise the intestinal barrier, triggering the cascade amplification of inflammatory signals. This leads to a synchronized assault on peripheral metabolic organs, pancreatic islets, and the CNS, ultimately establishing a self-reinforcing vicious cycle that drives both insulin resistance and β-cell failure123,124. The “spark” of metabolic inflammation originates from gut ecological dysbiosis and the disruption of local immune homeostasis by its messengers. The hallmark of gut microbiota dysbiosis is a reduction in beneficial bacteria, such as SCFA producers, and an increase in potentially pathogenic bacteria, which directly shifts the balance of chemical and immune signals within the gut. On one hand, messengers with anti-inflammatory and barrier-enhancing properties, such as butyrate, are diminished125; on the other hand, PAMPs like LPS increase. LPS activates the Toll-like receptor4 (TLR4)/myeloid differentiation factor 88 (MyD88) pathway, initiating downstream inflammatory signaling cascades such as IKK and MAPK pathways, thereby damaging the intestinal barrier126. EVs derived from pathogenic bacteria carry endotoxins that inhibit tight junction protein expression (e.g., Occludin and ZO-1), exacerbating barrier damage57. Diet is a key regulatory factor at this stage: a Western-style diet aggravates this process, while dietary fiber interventions enrich beneficial bacteria such as Akkermansia, thereby improving intestinal barrier function127. The disruption of the intestinal barrier increases intestinal permeability, allowing large amounts of microbial products such as LPS to leak into the portal vein and systemic circulation, resulting in metabolic endotoxemia. This constitutes the starting point for the abnormal immune activation of the gut-brain axis128,129. These gut-derived inflammatory messengers then undergo systemic dissemination via the humoral circulation within the MGBA, enabling their synchronous effects on peripheral target organs and the CNS. As detailed in Section 4.1, these inflammatory mediators induce hepatic insulin resistance via Kupffer cell activation and JNK/IKK-mediated IRS-1 phosphorylation. Beyond the liver, circulating inflammatory signals spread to skeletal muscle and adipose tissue, disrupting their insulin signaling via analogous JNK/IKK pathways. This also promotes the release of more free fatty acids and inflammatory factors from adipose tissue, further exacerbating the systemic inflammatory state130,131. Furthermore, this systemic inflammatory environment damages the pancreas. IL-1β and TNF-α activate NF-κB within the islets, suppressing β-cell function and promoting β-cell apoptosis132. Recent studies have also revealed that bacterial extracellular vesicles (BEVs) originating from the gut microbiota accumulate in the pancreatic β-cells of obese individuals, where their bacterial DNA activates the cGAS/STING pathway, promoting islet inflammation and impairing β-cell function, thereby providing evidence for direct gut-islet communication122. More importantly, this systemic inflammatory reaches the CNS, thereby completing the loop of the MGBA immune pathway and intertwining with other pathways to form a self-reinforcing cycle. Circulating LPS and pro-inflammatory cytokines (e.g., IL-6, TNF-α) cross the blood-brain barrier or act on circumventricular organs, activating microglia in the hypothalamus and triggering central neuroinflammation112. This directly impairs insulin signaling in hypothalamic neurons, exacerbating central insulin resistance, and may alter autonomic output, thereby worsening peripheral glucose metabolism regulation101. Additionally, hyperglycemia itself can feedback to exacerbate gut dysbiosis by increasing intestinal permeability133. Conversely, the peripheral insulin resistance and β-cell damage intensified by inflammation lead to more severe metabolic disorders, which in turn provide fertile ground for sustained inflammation. Therefore, in T2DM, metabolic inflammation clearly delineates a pathological axis that traverses the entire MGBA. This axis originates from gut microbiota dysbiosis and the associated imbalance of microbial messengers, leading to intestinal barrier disruption and the collapse of the immune defense line. This, in turn, triggers metabolic endotoxemia and the systemic dissemination of inflammatory signals. These systemic inflammatory signals, on one hand, cause peripheral insulin resistance and islet β-cell damage, and on the other hand, ascend to the CNS, inducing neuroinflammation in key brain regions such as the hypothalamus. Within this cycle, the immune pathway is deeply intertwined with the neural and endocrine pathways, rendering inflammation both a consequence of MGBA dysregulation and a core driving force propelling it towards more severe stages of decompensation. Interventions targeting this pathway—--such as repairing the intestinal barrier and remodeling the microbiota through probiotics, specific dietary components, or anti-inflammatory strategies to quell the systemic inflammatory storm—have emerged as a crucial strategic direction for preventing and treating T2DM by targeting the MGBA134–136, see Fig. 3.Fig. 3The dynamic mechanism of MGBA dysregulation in the progression of T2DM.This schematic illustrates the pathological progression of T2DM, corresponding to three core mechanisms. (Left panel): Dysregulated microbial messengers trigger central and peripheral insulin resistance (IR), establishing a mutual reinforcement loop between the disrupted gut, brain, and peripheral organs. (Middle panel): Sustained IR and systemic stressors (glucolipotoxicity, ER/mitochondrial stress, and inflammation) drive β-cells dedifferentiation and death, causing loss of secretory identity and function. (Right panel): Gut-derived metabolic endotoxemia and systemic dissemination of inflammatory messengers create a self-fueling vicious cycle—intertwining neuroinflammation, liver inflammation, and further gut dysbiosis—thereby perpetuating hyperglycemia and disease progression. Created in BioRender. Ma, K. (2026). BioRender.com/hw7nh41. The dynamic mechanism of MGBA dysregulation in the progression of T2DM. This schematic illustrates the pathological progression of T2DM, corresponding to three core mechanisms. (Left panel): Dysregulated microbial messengers trigger central and peripheral insulin resistance (IR), establishing a mutual reinforcement loop between the disrupted gut, brain, and peripheral organs. (Middle panel): Sustained IR and systemic stressors (glucolipotoxicity, ER/mitochondrial stress, and inflammation) drive β-cells dedifferentiation and death, causing loss of secretory identity and function. (Right panel): Gut-derived metabolic endotoxemia and systemic dissemination of inflammatory messengers create a self-fueling vicious cycle—intertwining neuroinflammation, liver inflammation, and further gut dysbiosis—thereby perpetuating hyperglycemia and disease progression. Created in BioRender. Ma, K. (2026). BioRender.com/hw7nh41. Mechanism-guided therapeutic interventions: targeting the gut-brain axis pathways Building upon the core mechanistic role of the MGBA in obesity and T2DM as outlined above, intervention strategies are evolving from traditional macronutrient management toward precisely targeting the microscopic nodes of this communication network137. Current research primarily focuses on three complementary strategies: reshaping the gut ecosystem to increase beneficial messengers, directly mimicking or blocking the receptor signals of microbial messengers, and restoring the integrity of gut-brain dialogue through neuromodulation138. Collectively, these strategies represent a paradigm shift in the therapeutic approach to metabolic diseases. Ecological remodeling strategies: promotion of beneficial microbial messengers by prebiotics and probiotics Ecological remodeling strategies are designed to positively shape the gut microbiota environment through supplementation with exogenous substances, thereby indirectly increasing the output of beneficial microbial messengers and strengthening the protective signals of the MGBA at their source. Prebiotics and probiotics form the cornerstone of this approach. Prebiotics are indigestible food components found in fermentable dietary fibers, such as inulin and β-glucan, which selectively stimulate the growth and activity of beneficial microorganisms in the colon139. Probiotics, such as bifidobacteria and lactobacilli, are live microorganisms with documented health benefits. They exert their beneficial effects through direct supplementation, competitive exclusion, and niche protection. The two are often used in combination to achieve superior synergistic intervention outcomes140,141. The core mechanism by which prebiotics and probiotics improve metabolic health lies primarily in enhancing intestinal barrier function and reducing metabolic endotoxemia. For example, probiotics can upregulate tight junction proteins, thereby reducing intestinal permeability142,143. Similarly, prebiotics such as galactooligosaccharides strengthen the intestinal barrier by increasing beneficial bacteria abundance. This significantly reduces LPS levels in portal vein plasma, alleviating high-fat diet-induced systemic low-grade inflammation144. This action curbs the generation and amplification of gut-derived inflammatory signals at their source. A more critical pathway of action involves promoting the production of beneficial microbial metabolites, particularly SCFAs. SCFAs not only serve as energy substrates for the host but are also important signaling molecules that broadly regulate host endocrine and metabolic homeostasis via receptors such as GPR41/GPR43145. Multiple studies have detailed the downstream effects of SCFAs. For example, Poria cocos polysaccharides improve insulin sensitivity by modulating the gut microbiota, increasing SCFAs, and activating the adipose tissue FGF21/PI3K/AKT signaling axis and GLUT4 expression146. Lactobacillus plantarum (LPP) activates lipid oxidation pathways in adipose tissue and restores hepatic insulin signaling by increasing microbial metabolites like butyrate, thereby alleviating obesity and metabolic dysfunction147. Dendrobium officinale polysaccharide (DOP) increases SCFA levels, increases SCFA levels, upregulates FFAR2/FFAR3 expression, stimulates GLP-1 and PYY secretion, and consequently repairs islet function and improves insulin resistance148. Additionally, interventions with prebiotics and probiotics can enrich specific bacterial species, such as B. acidifaciens, promoting the synthesis of key beneficial metabolites like pentadecanoic acid (C15:0). This, in turn, activates AMPK and PPARα/γ while inhibiting multiple inflammatory pathways, demonstrating anti-inflammatory and metabolic protective activities149. Therefore, ecological remodeling strategies work by multi-targeted, systematic enhancement of the beneficial signaling pathways within the MGBA, including the release of SCFAs, activation of GPCRs, and stimulation of incretin hormone secretion, see Fig. 4.Fig. 4Mechanism-guided therapeutic interventions targeting the MGBA.The illustration delineates three complementary therapeutic approaches for metabolic diseases (obesity and T2DM). (Left) Ecological Remodeling Strategies: Prebiotics and probiotics reshape the gut ecosystem, enriching beneficial bacteria that produce SCFAs. SCFAs restore intestinal barrier integrity (reducing metabolic endotoxemia) and activate GPR41/43 on EECs to stimulate GLP-1 and PYY release, thereby improving systemic insulin sensitivity. (Middle) Receptor-Targeted Strategies: Synthetic agonists directly target specific GPCRs (including GPR41, GPR43, GPR40/120, and TGR5) or block Toll-like receptors (TLR2/TLR4), providing precise organ-specific metabolic protection (e.g., preserving β-cells, resolving fatty liver, and shielding the kidneys from inflammatory damage). (Right) Systems Integration Strategy (Neuromodulation): Vagus nerve stimulation—achieved via implantable stimulators, transcutaneous auricular VNS (taVNS), or oral mechanostimulating capsules—restores gut-brain communication. This modulation regulates satiety via gut-derived neurohormones (PYY/Flagellin signaling), activates the HPA axis for anti-inflammatory cortisol release, and triggers the cholinergic anti-inflammatory pathway to promote M2 macrophage polarization. Created in BioRender. Ma, K. (2026). BioRender.com/ona0irx. Mechanism-guided therapeutic interventions targeting the MGBA. The illustration delineates three complementary therapeutic approaches for metabolic diseases (obesity and T2DM). (Left) Ecological Remodeling Strategies: Prebiotics and probiotics reshape the gut ecosystem, enriching beneficial bacteria that produce SCFAs. SCFAs restore intestinal barrier integrity (reducing metabolic endotoxemia) and activate GPR41/43 on EECs to stimulate GLP-1 and PYY release, thereby improving systemic insulin sensitivity. (Middle) Receptor-Targeted Strategies: Synthetic agonists directly target specific GPCRs (including GPR41, GPR43, GPR40/120, and TGR5) or block Toll-like receptors (TLR2/TLR4), providing precise organ-specific metabolic protection (e.g., preserving β-cells, resolving fatty liver, and shielding the kidneys from inflammatory damage). (Right) Systems Integration Strategy (Neuromodulation): Vagus nerve stimulation—achieved via implantable stimulators, transcutaneous auricular VNS (taVNS), or oral mechanostimulating capsules—restores gut-brain communication. This modulation regulates satiety via gut-derived neurohormones (PYY/Flagellin signaling), activates the HPA axis for anti-inflammatory cortisol release, and triggers the cholinergic anti-inflammatory pathway to promote M2 macrophage polarization. Created in BioRender. Ma, K. (2026). BioRender.com/ona0irx. Receptor-targeted strategies: precise intervention with microbial metabolite analogs and receptor antagonists Compared to indirect ecological remodeling, receptor-targeted strategies aim to directly mimic beneficial microbial messengers or block harmful signals, achieving more precise and efficient pharmacological modulation of MGBA nodes150. The development of agonists targeting receptors for beneficial messengers is a primary focus. Among these, GPCRs serve as one of the main targets, most of whose natural ligands--such as metabolites, fatty acids, peptides, or neurotransmitters--have already been identified151. For example, GPR41 and GPR43, expressed in adipocytes, colonic epithelial cells, and peripheral blood mononuclear cells, have been confirmed as potential targets for improving metabolic disorders21. While no candidate drugs have yet entered clinical trials, several synthetic agonists have shown promise in preclinical studies. For instance, the GPR41/43 agonist AR420626 reverses inflammation-induced increases in colonic permeability and inhibits the proliferation of hepatocellular carcinoma cells by inducing apoptosis152,153. The GPR43 agonist 4-chloro-α-(1-methylethyl)-N-2-thiazolyl-benzeneacetamide (4-CMBT) promotes β-cell proliferation and enhances β-cell function in obese states154. The GPR41 agonist AZ1729 counteracts β-adrenergic receptor agonist-induced lipolysis in primary mouse adipocytes155. Beyond SCFA receptors, other key metabolite pathways have also become a focal point for drug design. Aromatic amino acids produced from dietary protein hydrolysis, including tryptophan, phenylalanine, and tyrosine, are important precursors for microbial metabolites, and their downstream products serve as key signals mediating host-microbiota interactions156. Targeting their downstream pathways, the aryl hydrocarbon receptor ligand agonist indigo, in a diet-induced obesity mouse model, effectively induces the production of IL-10 and IL-22. By increasing intestinal Lactobacillus abundance, enhancing gut barrier function, and reducing endotoxemia, it alleviates insulin resistance and fatty liver157. Concurrently, activation of the BA receptor TGR5 also demonstrates renal protective effects. Its dual agonist INT-777 exerts protective effects in diabetic nephropathy by regulating multiple pathways, including mitochondrial biogenesis, antioxidant defense, and fatty acid oxidation158. Additionally, strategies for multi-target modulation of multiple metabolic-sensing receptors have also advanced. The fatty acid mimetic PBI-4547 functions simultaneously as a GPR84 antagonist and a GPR40/GPR120 agonist. In a DIO mouse model, it ameliorates overall metabolic dysregulation, reduces hepatic steatosis and inflammation--mechanisms associated with stimulating fatty acid oxidation and inducing the expression of genes for hepatic mitochondrial uncoupling proteins159. In blocking harmful inflammatory signals, the development of TLR antagonists has been particularly active. The TLR2 antagonist CU-CPT22 inhibits pro-inflammatory factors production in LPS-treated macrophages and promotes their polarization toward the anti-inflammatory M2 phenotype, alleviating neuropathic pain in a T2DM mouse model160. Similarly, LPS derived from Rhodobacter sphaeroides acts as a TLR4 antagonist, inhibiting IL-6 secretion from macrophages and endothelial cells stimulated by LPS or palmitate, and significantly reducing vascular inflammation and atherosclerosis in T2DM mice161. This strategy marks a leap in therapeutic philosophy from “modulating the microbiota” to “mimicking its beneficial functions” and “intercepting its harmful signals.” See Fig. 4. Systems Integration strategy: neuromodulation to restore gut-brain axis dialogue When the gut ecosystem and chemical signaling pathways are severely disrupted, directly modulating the “information superhighway” of the MGBA--the vagus nerve--offers a systemic therapeutic approach to restore gut-brain dialogue. Vagus nerve stimulation has shown significant potential in controlling food intake, body weight, and regulating energy metabolism. An implantable, battery-free vagus nerve stimulation system, designed to be spontaneously responsive to gastric movement, activates vagal afferent fibers via electrical signals, thereby reducing food intake and achieving effective weight control. This strategy has demonstrated clear efficacy in rat models, with the experimental group maintaining an average body weight of 350 g over 100 days, representing a 38% reduction compared to the control group162. On the other hand, non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) exerts its anti-obesity effects by promoting the browning of white adipose tissue. Studies have found that a 6-week taVNS intervention significantly reduced weight gain, body mass index, and the accumulation of inguinal and epididymal white adipose tissue in high-fat diet-induced obese rats. Concurrently, it increased the content and thermogenic activity of interscapular brown adipose tissue and improved mitochondrial structure and function163. Furthermore, the development of novel, orally administered self-powered electrostimulators offers an innovative approach to neuromodulation. These electrostimulators are composed of piezoelectric BaTiO₃ microparticles complexed with capsaicin. After ingestion, they selectively bind to capsaicin-sensitive sensory nerve terminals in the gastric mucosa. Under gastric peristalsis, they generate electrical signals that are transmitted via the gut-brain axis to the hypothalamus, where they enhance central satiety signaling, reduce food intake, and promote energy metabolism164. The mechanisms of vagus nerve action integrate the nervous, endocrine, and immune systems. The vagus nerve serves not only as a crucial sensor for gut endocrine hormones (including 5-HT, CCK, GLP-1, PYY, and ghrelin), but its activity is itself modulated by the gut microbiota. Microbiota dysbiosis leads to reduced vagal sensitivity to signals such as leptin165. Microbe-neuron interactions also play a key role: the common microbial pattern flagellin activates TLR5 on PYY-positive neuropod cells in the colon, promoting PYY release, which then acts on NPY2R in vagal ganglia. This subsequently inhibits feeding behavior via the gut-brain sensory neural circuit166. Furthermore, the vagus nerve exerts anti-inflammatory effects through two major pathways. The first is a neuroendocrine pathway, relying on the vagus nerve-NTS-PVH axis to activate the HPA axis, promoting the release of anti-inflammatory hormones such as cortisol167. The second is a neural pathway, namely the cholinergic anti-inflammatory pathway, which depends on vagal efferent fibers to modulate immune responses168. Studies have confirmed that the CNS regulates local pancreatic inflammation via the anti-inflammatory reflex. For example, specific activation of the cholinergic anti-inflammatory pathway induces M2 macrophage polarization, thereby reducing systemic inflammation and improving insulin sensitivity—an effect that can be reversed by acetylcholine receptor antagonists or macrophage depletion169. In summary, as the central hub of gut-brain dialogue, restoring vagus nerve function involves not only the regulation of feeding and metabolism but also extensive participation in immune and inflammatory modulation, thus providing an important neuromodulation target for interventions against obesity and related metabolic diseases. Therefore, neuromodulation strategies represent a direct intervention at the level of “information transmission,” offering a crucial tool for restoring the overall functional balance of the MGBA, see Fig. 4. Conclusion Obesity is a chronic and frequently relapsing disease accompanied by numerous metabolic, physical, and psychosocial complications, including a significantly increased risk for the development of T2DM170. It serves as a key pathophysiological driver for T2DM, other cardiovascular risk factors (such as hypertension, dyslipidemia, MASLD, and inflammatory states), as well as cardiovascular and renal diseases. Conversely, T2DM may further exacerbate obesity, partly through glucose-lowering therapies that promote weight gain, while obesity can worsen hyperglycemia and T2DM, creating a vicious cycle that accelerates disease progression and the onset of complications such as microvascular damage171. In recent years, the approval and introduction of various anti-obesity and glucose-lowering medications have enabled patients to achieve weight loss and glycemic control172. While understanding of the gut-brain axis has advanced significantly, the literature on obesity and T2DM still presents certain limitations. This review systematically elucidates how key “microbial messengers,” represented by SCFAs, BAs, neuroactive metabolites, and microbial EVs, constitute the MGBA through the three integrated pathways of neural, humoral, and immune communication, playing a pivotal driving role in the onset and development of obesity and T2DM. The dysregulation of these microbial messengers is not merely an epiphenomenon of metabolic diseases. Instead, by inducing hypothalamic dysfunction, driving adipose tissue inflammation, impairing incretin signaling, and triggering systemic metabolic inflammation, they actively participate in the full pathological continuum from positive energy balance to insulin resistance and β-cell failure. This mechanistic map holds significant implications for clinical translation. However, translating this promising paradigm into clinical practice faces multiple challenges. Future research must integrate multidimensional data, including host genetics, dietary patterns, and baseline microbiome profiles, to identify subpopulations responsive to specific interventions. In summary, the MGBA theory opens a novel perspective for understanding complex metabolic disorders such as obesity and T2DM. It repositions the gut--no longer viewed as an isolated digestive organ--as a central hub intricately connected to the brain and systemic metabolism, meticulously regulated by microbial messengers. By continuing to decipher the molecular language of this complex dialogue and innovatively developing targeted intervention strategies, we have the potential to fundamentally transform the paradigm for preventing and managing metabolic diseases, offering a powerful scientific framework to address this global public health challenge.